

Special Issue

Pleural Cavity Tumor Microenvironment: Primary and Metastatic Tumors

Message from the Guest Editors

Pleural effusion is a major diagnostic and therapeutic problem with more than 1.5 million patients suffering from this condition in the United States every year. Cancer is one of the commonest etiologies of pleural effusion, and both metastatic diseases and primary tumors show poor prognosis and urge for therapeutic advance. Immunotherapy has demonstrated promising results in various forms of cancer, and its utility in pleural diseases is under investigation. Furthermore, basic, and translational studies are trying to elucidate the role of the numerous factors of the tumor microenvironment, like inflammatory cells, vascular bed, extracellular matrix, extracellular vesicles, neural fibers in various forms of cancer, including the pleural cavity, which has unique physiological characteristics. This Special Issue aims to gather all recent development in the tumor microenvironment of the pleural cavity, in terms of basic and translational science, but also of clinical and therapeutic advance.

Guest Editors

Dr. Georgia Karpathiou

Department of Pathology, University Hospital of Saint-Etienne, Hôpital Nord, 42055 CEDEX 2, Saint Etienne, France

Prof. Dr. Marios Froudarakis

Department of Pneumology and Thoracic Oncology, University Hospital of Saint-Etienne, North Hospital, 42055 CEDEX 2, Saint Etienne, France

Deadline for manuscript submissions

closed (31 May 2022)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 8.0
Indexed in PubMed



mdpi.com/si/54811

Cancers
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 8.0
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)